Equity Overview
Price & Market Data
Price: $2.14
Daily Change: +$0.03 / 1.40%
Daily Range: $2.09 - $2.14
Market Cap: $14,809,093
Daily Volume: 3,538
Performance Metrics
1 Week: 3.43%
1 Month: -24.64%
3 Months: -34.27%
6 Months: -61.71%
1 Year: -95.13%
YTD: -38.66%
Company Details
Employees: 18
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.